New Data for Bioerodible DURAVYU in Wet AMD - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

New Data for Bioerodible DURAVYU in Wet AMD

Tarek S. Hassan provides perspective on the Phase 3 LUGANO topline results and the path forward for DURAVYU in wet age-related macular degeneration (AMD)

  • September 17, 2026

  • 5 min

Share

  • 1

    The LUGANO trial evaluated DURAVYU (EYP-1901) against aflibercept in wet AMD but did not meet the primary endpoint for visual acuity.

  • 2

    Nine DURAVYU patients experienced ≥15-letter vision loss from causes unrelated to neovascular AMD, impacting trial results.

  • 3

    DURAVYU demonstrated strong anatomic control and reduced treatment burden, with 76% of patients remaining supplement-free at Week 32.

  • 4

    The trial showed a 42% reduction in treatment burden compared to aflibercept, indicating fewer required injections.

  • 5

    The next Phase 3 trial, LUCIA, is expected to provide further data, with results anticipated in Q4 2026.

Original Source(s)

New Data for Bioerodible DURAVYU in Wet AMD

  • September 17, 2026

Related Content

Europe’s Cataract Benchmark

EUREQUO data from more than 363,000 procedures show improving visual outcomes and low complication rates across Europe

  • September 15, 2026

  • 2 min
Eyelash Extensions Under Scrutiny

Regular eyelash extension use linked to Demodex infestation, irritation, and meibomian gland dysfunction in a study of young women

  • September 13, 2026

  • 3 min
Coastal Eye Associates Welcomes Dr. Sanchay Gupta

Comprehensive ophthalmologist specializing in advanced cataract surgery joins Houston-area practice

  • September 7, 2026

  • 2 min